Fig. 3 | British Journal of Cancer

Fig. 3

From: Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours

Fig. 3

Immune checkpoint molecule expression according to different clinical settings TKI, tyrosine kinase inhibitor, IM-PD group, imatinib-progressed and no exposure to sunitinib or regorafenib, IM-PD/SU-treated, imatinib-progressed and sunitinib and/or regorafenib-treated a PD-1+ CD3+ per total CD3+; b PD-L1+ DOG-1+ per total DOG-1+; c TIM3+ CD3+ per total CD3+; d LAG3+ CD3+ per total CD3+

Back to article page